Salubris Biotherapeutics的动态

Bio-Thera Solutions has officially entered the Keytruda #biosimilar landscape with the First Patient In for our integrated Phase 1 / Phase 3 clinical trial. While we will face a lot of competition from other pembrolizumab biosimilars (there are many), there are just too many #cancer patients that will benefit from all the Keytruda biosimilars that get approved. #oncology #biosimilars https://lnkd.in/gWKnQUyH

An abstract of satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against Claudin18.2) has been accepted for oral presentation at the American Society of Clinical Oncology (“ASCO”) Annual Meeting 2024. Abstract Title Claudin18.2-Targeted Chimeric Antigen Receptor T Cell-Therapy for Patients with Gastrointestinal Cancers: Final Results of CT041-CG4006 Phase 1 Trial https://lnkd.in/gMjEjdr7 #ASCO2024 #cartcell #cartcelltherapy #oncology #gastriccancer #gastrointestinalcancer

MacroGenics, Inc. has shared data from the Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo, previously known as MGC018) in patients with metastatic castration-resistant prostate cancer (mCRPC). Early interim safety data from the Phase 2 TAMARACK study (NCT05551117), including?comparison to retrospective analysis from a Phase 1 study?(as submitted in an ASCO abstract that was not accepted), is included in the press release. Overall conclusions are: Preliminary safety data from TAMARACK suggest that reducing the dose and frequency of vobra duo improves its safety and tolerability in men with mCRPC. The company plans to provide updated interim data, including safety and preliminary efficacy, by May 31. #mabs #adcs https://lnkd.in/eE57D7mu

The drug, sold under the brand name Enhertu, originally won U.S. approval in late 2019 as a third-line treatment for HER-2-positive breast cancer patients, and the fresh approval opens the treatment across multiple HER2-expressing solid tumors. Enhertu belongs to a class of therapies called antibody-drug conjugates (ADC) and comprises a monoclonal antibody - in this case trastuzumab (also known as Herceptin) - chemically linked to a cell-killing chemotherapy drug. #Oncology #moniclonalantibody #Oncology #Enhertu https://lnkd.in/gf2RXecS

#AntibodyDrugConjugates are a class of #anticancer therapeutics delivering highly cytotoxic molecules directly to #cancercells. However, second-generation ADCs are looking to reduce toxicity and improve the magnitude and duration of response in #solidtumors. https://lnkd.in/gWAXUrwX #cancer #oncology #AACR #CancerResearch #AACR2024 #AACR24

The opportunity and privilege of witnessing data unfold from our DESTINY-Breast trials during recent American Society of Clinical Oncology (ASCO) meetings have been special moments for Daiichi Sankyo US and reflect the potential impact we can have on patients. When DESTINY-Breast04 was presented at #ASCO22 the energy and overwhelming sense of pride I shared with my teammates was profound. That experience stays with all of us and fuels us to continue to push to redefine the treatment landscape. Fast-forward two short years and we’re back at #ASCO24 with new data from our DESTINY-Breast06 phase 3 trial. Again, I find myself overwhelmed with pride, and energized by the promise of this new data for the future of cancer care. Results from the DESTINY-Breast06 phase 3 trial are a first for a HER2 directed medicine and signal of what the future could hold for certain people impacted by metastatic breast cancer. If congresses like #ASCO24 teach us anything, it is that there is still so much opportunity to improve the cancer treatment landscape. We must always seek to thoughtfully question the “status quo” and push beyond traditional boundaries all in the goal of helping people impacted by cancer.

Mythic Therapeutics, Inc. announced promising initial results from the Phase 1 KisMET-01 study of MYTX-011, a novel cMET-targeting ADC, in treating advanced or metastatic non-small cell lung cancer (NSCLC). The study, presented at the ASCO Annual Meeting, showed MYTX-011 was well-tolerated with no dose-limiting toxicity and demonstrated nearly dose-proportional pharmacokinetics. The study continues to assess safety, tolerability, and preliminary anti-tumor activity, with further efficacy data to be presented in the future. The findings offer hope for patients with diverse cMET expression levels. #HemiBio Brian Fiske https://lnkd.in/epvx2gPC

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting #stockmarket #stocks #investing #businessnews #trading #daytrading #clinicaltrial

A great review on agnostic antibody-drug conjugates (ADCs)! The paper discusses the use of ADCs as a targeted chemotherapy delivery system for treating solid tumors. It mentions several approved ADCs for specific types of cancer and highlights two promising ADCs for various cancer types. It also mentions ongoing clinical trials investigating ADCs for different solid tumors. Overall, the use of ADCs in cancer treatment shows promise for improving outcomes in a wide range of histologies. https://lnkd.in/dcyqncCF

We have recently received further information on the study which led to the FDA approval of Alectinib, a potent oral ALK (anaplastic lymphoma kinase) tyrosine kinase inhibitor. According to Dr. Anish K. Shah, "The approval was given based on findings from the ALINA study, an international, randomized, open-label trial that involved ALK-positive NSCLC patients who underwent complete tumor resection." Read more about the details of the study here ? https://lnkd.in/gXstbnpr